Weihai Baihe Biology Technological Co., Ltd. Class A

Weihai Baihe Biology Technological Co., Ltd. Class A

SSSE:603102
31.78
CNY
-0.28
(-0.87%)
2.04EPS
20.54P/E
2.39BMarket Cap
Apr 21Next Earn

Total Valuation

CNY

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A carries a market capitalization of 2.39B, placing it among publicly traded companies globally. Its enterprise value stands at 1.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.39B
Enterprise Value1.34B

Important Dates

Weihai Baihe Biology Technological Co., Ltd. Class A's next confirmed earnings release is scheduled for April 21, 2027.

Earnings Date4/21/2027

Share Statistics

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A has 64.00M shares outstanding.

Shares Outstanding64.00M

Valuation Ratios

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 20.54. The price-to-sales ratio is 2.35, and the price-to-book ratio stands at 1.41.

PE Ratio20.54
PS Ratio2.35
PB Ratio1.41
P/TBV Ratio1.49

Enterprise Valuation

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A trades at an EV/EBITDA multiple of 9.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.34B versus a market cap of 2.39B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.36
EV / EBITDA9.04
EV / EBIT9.04

Financial Position

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.10, indicating moderate leverage, while an interest coverage ratio of 110.78 demonstrates strong ability to service its debt obligations.

Current Ratio6.63
Quick Ratio5.02
Debt / Equity1.10
Debt / EBITDA0.13
Interest Coverage110.78

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A posted a return on equity (ROE) of 6.74, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.89, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.88, useful for judging operating efficiency across full business cycles. The company generates approximately 902,403.19 in revenue per employee across its workforce of 1,096.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.68 indicates how many times Weihai Baihe Biology Technological Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.74
Return on Assets (ROA)5.89
Return on Invested Capital (ROIC)7.46
Return on Capital Employed (ROCE)5.88
Revenue Per Employee902,403.19
Employee Count1,096.00
Inventory Turnover4.68

Taxes

CNY

Over the twelve months ended September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A recorded 19.62M in income tax expense. That works out to an effective tax rate of 13.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 146.84M, leaving 113.33M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax19.62M
Effective Tax Rate13.36

Stock Price Statistics

CNY

As of the close on November 17, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A's stock has declined approximately 28.38% over the past 52 weeks. The 50-day moving average sits at 35.29, while the 200-day moving average is 38.24.

52-Week Price Change-28.38%
50-Day Moving Average35.29
200-Day Moving Average38.24

Income Statement

CNY

Over the twelve months ended September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A generated 989.03M in revenue and converted that into 113.33M in net income, yielding earnings per share of 2.04. EBITDA reached 148.32M, while operating income came in at 157.61M.

Revenue989.03M
Gross Profit352.44M
Operating Income157.61M
Pretax Income146.84M
Net Income113.33M
EBITDA148.32M
EBIT148.32M
Earnings Per Share (EPS)2.04

Balance Sheet

CNY

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A holds 1.10B in cash and equivalents against 18.93M in total debt, resulting in a net debt position of -1.10B. Total book value stands at 1.69B, with working capital of 1.24B providing operational flexibility.

Cash & Cash Equivalents1.10B
Total Debt18.93M
Net Debt-1.10B
Equity (Book Value)1.69B
Book Value Per Share26.37
Working Capital1.24B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-37.49M

Margins

Over the twelve months ended September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A posted a gross margin of 35.63, reflecting its pricing power and cost economics. The operating margin of 15.94 and net profit margin of 11.46 provide insight into operational efficiency.

Gross Margin35.63
Operating Margin15.94
Pretax Margin14.85
Profit Margin11.46
EBITDA Margin15.00

Dividends & Yields

Over the twelve months ended September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Weihai Baihe Biology Technological Co., Ltd. Class A shareholders.

Shareholder Yield2.20

Scores

As of September 30, 2026, Weihai Baihe Biology Technological Co., Ltd. Class A has an Altman Z-Score of 7.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.99